Amgen Inc. (AMGN)
2 Magnificent Stocks to Buy That Are Near Their 52-Week Lows
Some investors believe you make money when you buy a stock, not when you sell it. The logic behind this idea is that investing in the right stock at the right time -- and holding onto it for a while -- is one of the best formulas for earning terrific returns.
Amgen (AMGN) Stock Falls Amid Market Uptick: What Investors Need to Know
In the most recent trading session, Amgen (AMGN) closed at $267.10, indicating a -1.14% shift from the previous trading day.
Why Amgen (AMGN) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Amgen Inc. (AMGN) 43rd Annual J.P. Morgan Healthcare Conference 2025 (Transcript)
Amgen Inc. (NASDAQ:AMGN ) 43rd Annual J.P. Morgan Healthcare Conference 2025 January 13, 2025 6:00 PM ET Company Participants Robert Bradway - Chairman, CEO & President Conference Call Participants Chris Schott - JPMorgan Chris Schott Good afternoon, everybody.
Why Amgen (AMGN) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Amgen (AMGN) Advances While Market Declines: Some Information for Investors
Amgen (AMGN) closed at $262.05 in the latest trading session, marking a +1.34% move from the prior day.
Amgen (AMGN) Stock Sinks As Market Gains: Here's Why
Amgen (AMGN) concluded the recent trading session at $258.59, signifying a -1.01% move from its prior day's close.
Will Amgen (AMGN) Beat Estimates Again in Its Next Earnings Report?
Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Amgen: The Buying Opportunity Has Now Arrived (Rating Upgrade)
Since my previous article, shares of Amgen meaningfully lagged the S&P 500 index. The company's revenue and non-GAAP EPS climbed higher in the third quarter. Amgen's deleveraging efforts are progressing, and the company is on pace to return to its pre-Horizon capital structure by the end of 2025.
Amgen: Blockbusters, Emerging Therapies, And Investment Potential
Amgen's strong product portfolio and pipeline developments, including, but not limited to, IMDELLTRA and MariTide, support a "Strong Buy" rating for long-term investors despite upcoming patent expirations. The company reported 24% YoY revenue growth in Q3 2024, with 10 products generating over $1 billion in revenue and six showing over 30% growth. Financial health remains robust with a 22% revenue increase in 9M 2024, though net income decreased due to Horizon Therapeutics acquisition costs.
Big Blue Chip Dividends? Try These ‘Dogs' Up To 6.8%
The Dogs of the Dow 2025 pay big dividends—up to 6.8%! Collectively they yield three-times what the broader market pays.
